Cited by The missing link? LGMN connects hypoxia and immunosuppression in glioblastoma

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives DOI

Hao Lin,

Chaxian Liu,

An-Kang Hu

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: May 8, 2024

Abstract Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, exploration of emerging modalities such as immunotherapy integration medicine engineering technology therapy, efficacy these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny inhibitory milieu within GBM has underscored significance cellular constituents microenvironment their interactions with cells neurons. Novel immune targeted therapy strategies have emerged, offering promising avenues for advancing treatment. One pivotal mechanism orchestrating immunosuppression involves aggregation myeloid-derived suppressor (MDSCs), glioma-associated macrophage/microglia (GAM), regulatory T (Tregs). Among these, MDSCs, though constituting minority (4–8%) CD45 + GBM, play central component fostering evasion propelling tumor progression, angiogenesis, invasion, metastasis. MDSCs deploy intricate mechanisms that adapt dynamic (TME). Understanding interplay between provides compelling basis This review seeks elucidate inherent explore existing targets, consolidate insights into MDSC induction contribution immunosuppression. Additionally, comprehensively surveys ongoing clinical trials potential strategies, envisioning future where targeting could reshape landscape GBM. Through synergistic other modalities, this approach can establish multidisciplinary, multi-target paradigm, ultimately improving prognosis quality life patients

Language: Английский

Citations

Immunotherapy for glioblastoma: current state, challenges, and future perspectives DOI

Yang Liu, Zhou Fei, Heba Ali

et al.

Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(12), P. 1354 - 1375

Published: Oct. 15, 2024

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard care offers minimal clinical benefit, most GBM patients experience recurrence after treatment. In recent years, significant advancements have been made the development novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance many advanced cancers. However, benefit immune-based treatments limited because unique immune profiles, cell heterogeneity, immunosuppressive microenvironment. this review, we present a detailed overview current immunotherapeutic discuss challenges potential molecular mechanisms underlying GBM. Furthermore, provide in-depth discussion regarding GBM, which will likely require combination therapies.

Language: Английский

Citations

Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments DOI

Lisa Feldman

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 26, 2024

Glioblastoma (GBM) tumors are the most aggressive primary brain in adults that, despite maximum treatment, carry a dismal prognosis. GBM exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring proliferation inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, CAR-T therapy, represent promising avenues for treatment. However, challenges such as heterogeneity, TME, BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, combination therapies targeting actively being explored improve outcomes patients. Targeting hypoxia immunotherapy represents potential strategy enhance treatment efficacy.

Language: Английский

Citations

Recent Advances in Biomimetic Strategies for the Immunotherapy of Glioblastoma DOI

Haoyu You,

Shuo Geng,

Shangkuo Li

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 311, P. 122694 - 122694

Published: June 28, 2024

Language: Английский

Citations

Epigenetic regulation of tumor-immune symbiosis in glioma DOI

Yang Liu, Heba Ali, Fatima Khan

et al.

Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(5), P. 429 - 442

Published: March 7, 2024

Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types therapies, including immunotherapies. Epigenetic reprogramming key molecular hallmark in tumors across cancer types, glioma. Mounting evidence highlights pivotal role epigenetic regulation shaping tumor biology therapeutic responses through mechanisms involving both cells immune cells, as well their symbiotic interactions the microenvironment (TME). In this review, we discuss that impacts cell immunity cell-autonomous non-cell-autonomous manner. Moreover, provide an overview potential approaches can disrupt epigenetic-regulated tumor-immune symbiosis TME.

Language: Английский

Citations

Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma DOI

Junju Chen,

Yixin Gao, Jian Zhong

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: unknown, P. 101806 - 101806

Published: Oct. 1, 2024

Language: Английский

Citations

Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review DOI

Emir Begagić, Hakija Bečulić,

Amina Džidić-Krivić

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 2089 - 2089

Published: May 30, 2024

Background: The study aims to investigate the role of hypoxia-inducible factors (HIFs) in development, progression, and therapeutic potential glioblastomas. Methodology: study, following PRISMA guidelines, systematically examined hypoxia HIFs glioblastoma using MEDLINE (PubMed), Web Science, Scopus. A total 104 relevant studies underwent data extraction. Results: Among studies, global contributions were diverse, with China leading at 23.1%. most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) frequently studied, followed by 2 (HIF2α), osteopontin, cavolin-1. Commonly associated pathways include glucose transporter (GLUT1) 3 (GLUT3) receptors, vascular endothelial growth (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target rapamycin (mTOR) pathway, reactive oxygen species (ROS). HIF expression correlates various hallmarks, including survival, neovascularization, metabolism, migration, invasion. Conclusion: Overcoming challenges such as treatment resistance absence biomarkers is critical effective integration HIF-related therapies into aim optimizing patient outcomes.

Language: Английский

Citations

Multi-omics analysis identifies sex-specific hepatic protein-metabolite networks in yellow catfish (Pelteobagrus fulvidraco) exposed to chronic hypoxia DOI

Cheng Zhao,

Yufeng Song,

Guosong Zhang

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 268, P. 131892 - 131892

Published: April 25, 2024

Language: Английский

Citations

Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer DOI

Guanjun Li,

Xiaohan Liu,

Chunhui Gu

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Aug. 3, 2024

An increasing number of clinical studies have begun to explore combination strategies with immune checkpoint inhibitors, aiming present new opportunities for overcoming anti-PD-1 treatment resistance in gastric cancer. Unfortunately, the exploration certain inhibitor has yielded suboptimal results. Therefore, it is necessary comprehensively analyze expression patterns checkpoints and identify optimal regimens inhibitors other inhibitors.

Language: Английский

Citations

Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy DOI

Houshi Xu, Huihui Chai, Ming Chen

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Oct. 7, 2024

Abstract Background Glioma is the most common primary malignant tumor in brain, and even with standard treatments including surgical resection, radiotherapy, chemotherapy, long-term survival rate of patients remains unsatisfactory. Recurrence one leading causes death glioma patients. The molecular mechanisms underlying recurrence remain unclear. Methods Our study utilized single-cell sequencing, spatial transcriptomics, RNA-seq data to identify a subtype FN1 + tumor-associated macrophages (FN1 TAMs) associated recurrence. Results This revealed an increased abundance TAMs recurrent gliomas, indicating their potential involvement as critical factor A negative correlation was observed between gliomas interval time recurrence, suggesting poor prognosis for high levels TAMs. Further investigation showed that were enriched hypoxic regions, implying metabolic changes tumors drive production recruitment Additionally, found contribute regulation immunosuppressive microenvironment might serve indicator patients’ sensitivity immunotherapy. Finally, we developed user-friendly website, PRIMEG ( http://www.szflab.site/PRIMEG/ ), exploring immune gliomas. Conclusion findings highlight providing new insights into therapeutic targets. Moreover, hold promise predicting therapy response aiding more precise risk stratification

Language: Английский

Citations